

2024 Superconvergence biorevolution series: Rise of the self-driving lab

Published 19 August 2024

Christopher Gannatti, CFA

Global Head of Research

Key Takeaways

- The drug discovery process is inefficient because we spend a lot of time and money and have a very low chance of success when looking at any new potential molecule. AI may be a tool that can help this process get better.
- Exscientia is one company that is an example of using AI to enhance the drug discovery process. We spoke to them on a recent episode of our [Next Big Thing podcast](#).
- Nvidia has been emphasising its 'omniverse' platform as a way in which different industries may accelerate how AI can help them speed forward certain critical developments. The omniverse could be a very interesting intersection with the 'self-driving lab.'
- Related Products WisdomTree BioRevolution UCITS ETF – USD Acc, WisdomTree Artificial Intelligence UCITS ETF – USD Acc [Find out more](#)

When constructing our [Biorevolution strategy](#), we worked alongside futurist [Dr Jamie Metzl](#), who is a member of the World Health Organization's expert committee on human genome editing. We believe that we are on the precipice of a remarkable period, which could last a few decades, where we challenge and ultimately evolve how we do things, such as:

- How we handle human health care
- How we grow food for an expanding global population
- How we generate novel materials, chemicals and energy from biological sources
- How we think about storing massive amounts of data with higher density and fidelity than we have in the past

Dr Metzl recently published the book [Superconvergence: How the Genetics, Biotech, and AI Revolutions will Transform our Lives, Work and World](#). Over the summer, we will publish a series of blogs that draw attention to some of the ideas presented in the book.

The bottom line

Thematic investing, in a sense, is about storytelling. Superconvergence does a great job conveying the narrative behind the [WisdomTree BioRevolution ESG Screened Index](#).

You've heard of the self-driving car—what about the self-driving lab

Imagine that you are about to take on a new task, but you have to consider the following details¹:

1. The task could take roughly 10 years, possibly longer, before you know it is complete.
2. The budget required would be in the range of \$1 billion, but likely more.
3. The chance of success, meaning you choose to follow a particular path which allows you to progress fully to the finish without needing to restart efforts, is about 5-10%.

Such a task, or a business arranged around the completion of such a task, does not appear very attractive. However, these are roughly the statistics involved in developing a new drug from start to finish.

Exscientia: using AI to improve the drug discovery process

On 7 June 2024, we released a conversation that we had with Exscientia on our [Next Big Thing podcast](#). This company is focused on utilising AI in an attempt to improve different phases of the drug discovery process.

AI represents a new set of tools that we can use to get closer to evaluating different compounds that might be effective drugs or therapies against different diseases. Importantly, the framing of this problem is not 'suddenly AI will save us and create all of these new drugs', but rather that we as a society are currently spending, through our pharmaceutical industry, hundreds of billions of dollars attempting to create new drugs.

What if a new set of tools were to become available that would help us have a more efficient drug discovery process? This is what AI can provide.

The self-driving lab: Connecting the software world with the physical world

From *Superconvergence*²:

Researchers across the globe are now working to build new models of "self-driving laboratories," bringing together AI systems and advanced, high-throughput automated machines to help shift the drug discovery and testing process, and all of human-engineered biology for that matter, into superdrive. These automated labs are able to rapidly carry out thousands or even millions of experiments selected by machine learning algorithms to achieve objectives defined by human researchers. A January 2023 Nature paper estimated that this process can increase a human expert's overall research productivity by an estimated thirty times, enabling the humans to reallocate their energies toward exploring tougher scientific questions.

We frequently write about AI. So far, the markets have been very excited about graphics processing units (particularly those from Nvidia) and different software platforms. We have been thinking about how we may be on the cusp of seeing much more capable robots. Still, we are not yet seeing investors getting excited about robotics more specifically.

Robotics could be the critical link between a world of virtual reality or digital twins and the physical world. Whether one is thinking of a new drug or a new material, it's not enough to have a system that works well within the confines of a virtual system—it also needs to prove out in the physical world and stand the test of real-world experimentation.

Conclusion: Convergence of Nvidia's omniverse with the world of laboratory science

As we write these words, Nvidia has just attained the status of the world's most valuable company³. Many are familiar with the company's revolutionary graphics processing units (GPUs), but in listening to CEO and founder Jensen Huang speak at GTC in March 2024 and then at Computex in Taiwan in June 2024, it's clear that Nvidia wants to be seen across the entire tech stack. One of their most interesting discussions regards the 'omniverse⁴.'

The omniverse looks like a domain-specific virtual reality world where various simulations can be run. It's not much of a leap to imagine how something like the omniverse could ultimately be empowered to drive the hardware of a self-driving lab at some point in the future. In this way, we can see how a market juggernaut, Nvidia, can be connected to a more currently esoteric concept, the self-driving lab. It may not be long until we see self-driving labs proliferating more widely.

1 Source: Lohr, Steve. "How A.I. is Revolutionizing Drug Development." New York Times. June 17, 2024.

2 Source: Metzl, Jamie. Superconvergence: How the Genetics, Biotech, and AI Revolutions will Transform our Lives, Work and World. Timber Press: 2024.

3 Source: Hamilton, Anita & Adam Clark. "Nvidia Is the World's Most Valuable Company. Can It Hold On to the Crown?" Barron's. June 18, 2024.

4 Source: <https://www.nvidia.com/en-us/omniverse/>

Important Risks Related to this Article

Important Information

Marketing communications issued in the European Economic Area (“EEA”): This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Marketing communications issued in jurisdictions outside of the EEA: This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

For professional clients only. The information contained in this document is for your general information only and is neither an offer for sale nor a solicitation of an offer to buy securities or shares. This document should not be used as the basis for any investment decision. Investments may go up or down in value and you may lose some or all of the amount invested. Past performance is not necessarily a guide to future performance. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.

The application of regulations and tax laws can often lead to a number of different interpretations. Any views or opinions expressed in this communication represent the views of WisdomTree and should not be construed as regulatory, tax or legal advice. WisdomTree makes no warranty or representation as to the accuracy of any of the views or opinions expressed in this communication. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice.

This document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares or securities in the United States or any province or territory thereof. Neither this document nor any copy hereof should be taken, transmitted or distributed (directly or indirectly) into the United States.

Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.